Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon

Public access to AEDs is growing, so why aren't they being used?

Automated external defibrillators might be increasingly available and encouraged for public use in the case of out-of-hospital cardiac arrests (OHCA), but a study recently published in the European Heart Journal found they aren’t being used nearly as much as they should be.

Thumbnail

HER2-targeted breast cancer treatments come with cardiovascular risks

Cardiotoxicity has been documented as a risk in cancer patients undergoing certain breast cancer therapies, but widely accepted international guidelines do not exist for dealing with those complications.

Boston Scientific Announces U.S. FDA Approval for MRI Labeling on High-Voltage Devices and U.S. Launch of Resonate™ Devices with the HeartLogic™ Heart Failure Diagnostic

MARLBOROUGH, Mass., Sept. 25, 2017 — Boston Scientific (NYSE: BSX) has launched the Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the HeartLogic™ Heart Failure Diagnostic to help physicians improve heart failure (HF) management.

Thumbnail

Umbilical cord stem cells could treat heart failure

A new treatment using stem cells from the umbilical cord increased ejection fraction and improved quality of life in heart failure patients, according to a study published in Circulation Research.

Researchers debut practice of monitoring mitochondria to predict, prevent cardiac arrest

New technology developed by researchers at Boston Children’s Hospital in conjunction with Cambridge-based Pendar Technologies has the ability to monitor oxygen levels in human tissue and predict cardiac arrest in heart patients, a study published in Science Translational Medicine reports.

Thumbnail

FDA approves pump to treat right heart failure

The FDA has granted pre-market approval to the Impella RP heart pump used in treating right heart failure, Abiomed announced Sept. 20.

Boston Scientific Announces Positive Late-Breaking Clinical Trial Data for the HeartLogic™ Heart Failure Diagnostic

Boston Scientific (NYSE: BSX) today announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study evaluating the performance of the HeartLogic™ Heart Failure Diagnostic to predict impending heart failure (HF) decompensation.

Thumbnail

Abbott's PA sensor system is clinically proven to work—but how safe is it?

Recent studies have proven Abbott’s wireless pulmonary artery (PA) sensor CardioMEMS HF System to be successful in reducing heart failure hospitalizations and dramatically lowering medical costs, but a study published in the Journal of the American Medical Association this month questions the safety of the device.

Displaying 729 - 736 of 1270

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.